Naringenin Inhibited Migration and Invasion of Glioblastoma Cells Through Multiple Mechanisms
Overview
Toxicology
Authors
Affiliations
Glioblastoma (GBM) is the most mortality brain cancer in the world. Due to high invasion and drug resistance cause the poor prognosis of GBM. Naringenin, an ingredient of citrus, exhibits many cellular functions such as antioxidant, anti-inflammation, and anticancer. Naringenin inhibits the migration of bladder and lung cancer via modulation of MMP-2 and/or MMP-9 activities, Naringenin inhibits migration and trigger apoptosis in gastric cancer cells through downregulation of AKT pathway. However, the effects of naringenin in GBM still remain to be elucidated. In this study, we reveal the molecular mechanisms of naringenin in the inhibition of migration and invasion in GBM. No overt alternation of cell proliferation was found in of GBM 8901 cells treated with different concentration of naringenin. Slight decreased cell viability was found in GBM 8401 cell treated with 200 and 300 μM naringenin. Significant reduction of migration and invasion as assayed by Boyden chamber analysis was found in of GBM cells treated with 100, 200, and 300 μM naringenin. Zymography analysis also revealed that the activities of MMP-2 and MMP-9 of GBM cells were significantly inhibited in response to 100, 200, or 300 μM naringenin treatment. Proteins of MMP-2 and MMP-9 were downregulated in naringenin treated GBM cells. In addition, naringenin also attenuated the activities of ERK and p38. Naringenin decreased mesenchymal markers (snail and slug) expression as revealed by Western blot analysis. Taken together, our findings indicated that naringenin eliminated the migration and invasion of GBM cells through multiple mechanisms including inhibition of MMPs, ERK, and p38 activities and modulation of EMT markers. Our results also suggested that naringenin may be a potential agent to prevent metastasis of GBM.
Whole Blood Transcriptome Analysis in Dairy Ewes Fed a Dietary Grape Pomace Supplementation.
Ianni A, Bennato F, Martino C, Saletti M, Pomilio F, Martino G Vet Sci. 2024; 11(11).
PMID: 39591310 PMC: 11599069. DOI: 10.3390/vetsci11110536.
de Santana M, Santos Y, Santos K, Santos Junior M, Victor M, Ramos G Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204085 PMC: 11356971. DOI: 10.3390/ph17080980.
Elsori D, Pandey P, Ramniwas S, Kumar R, Lakhanpal S, Rab S Front Pharmacol. 2024; 15:1406619.
PMID: 38957397 PMC: 11217354. DOI: 10.3389/fphar.2024.1406619.
Rajendran P Biomedicine (Taipei). 2024; 14(2):12-28.
PMID: 38939095 PMC: 11204124. DOI: 10.37796/2211-8039.1447.
Exploring the Therapeutic Potential of Flavonoids in the Management of Cancer.
Singh S, Verma R Curr Pharm Biotechnol. 2024; 26(1):17-47.
PMID: 38591206 DOI: 10.2174/0113892010297456240327062614.